Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889280 | 0.78 | ESR1 (0.42) | ALDH1A1HPGDKMT2AMAPTMEN1 | |
| SCHEMBL2099637 | 0.78 | IDO1 (0.48) | IDO1SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL1528053 | 0.76 | LDHA (0.52) | IDO1SMN1; SMN2DCUN1D1MAPK1ALDH1A1 | |
| SCHEMBL15125436 | 0.76 | GAA (0.52) | IDO1SMN1; SMN2DCUN1D1CASP3SENP8 | |
| SCHEMBL16112339 | 0.76 | PBRM1 (0.52) | IDO1SMN1; SMN2DCUN1D1MAPK1ALDH1A1 | |
| SCHEMBL10801976 | 0.76 | DCUN1D1 (0.43) | IDO1SMN1; SMN2DCUN1D1MAPK1ALDH1A1 | |
| SCHEMBL9173243 | 0.76 | IDO1 (0.47) | IDO1SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL11686059 | 0.76 | IDO1 (0.52) | IDO1SMN1; SMN2DCUN1D1ALDH1A1HPGD | |
| SCHEMBL6450194 | 0.74 | IDO1 (0.54) | IDO1SMN1; SMN2MAPK1HPGDKMT2A | |
| SCHEMBL6454308 | 0.74 | IDO1 (0.57) | IDO1SMN1; SMN2CASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538898-A1 | PROTHROMBIN TIME REAGENT COMPRISING AN IRON CHELATOR | Siemens Healthcare Diagnostics Products GmbH (DE) | 2019-09-18 | — | — | EP | claimed |
| CN-108727287-B | 1,2, 4-triazole compound and salt and application thereof | 东南大学 | 2020-10-27 | — | — | CN | disclosed |
| EP-2078009-B1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2313412-B1 | NOVEL DERIVATIVES OF PYRROLOINDOLE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI SA (FR) | 2013-01-02 | — | — | EP | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-8178687-B2 | Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof | SANOFI-AVENTIS (FR) | 2012-05-15 | — | — | US | disclosed |
| CN-102439003-A | Indazole derivatives inhibiting HSP90, compositions containing said derivatives and uses thereof | SANOFI AVENTIS | 2012-05-02 | — | — | CN | disclosed |
| US-8163750-B2 | Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| CN-102026992-A | Novel HSP90 inhibitory carbazole derivatives, compositions containing the same and uses thereof | SANOFI AVENTIS | 2011-04-20 | — | — | CN | disclosed |
| WO-2011027081-A2 | NOVEL DERIVATIVES OF 5,6,7,8-TETRAHYDROINDOLIZINE INHIBITING HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | WO | disclosed |
| EP-2265598-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | disclosed |
| WO-2009122034-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
| CN-101528735-A | Novel fluorene derivatives, compositions containing them and use as chaperone protein HSP90 inhibitors | SANOFI AVENTIS (FR) | 2009-09-09 | — | — | CN | disclosed |
| EP-2078009-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | Sanofi-Aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009004146-A2 | NOVEL HERBIMYCIN A ANALOGUE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008049994-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2008-05-02 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010241-A1 | HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | IDO1 1789/4885ADORA2A 2681/4885SMN1; SMN2 3164/4885 |
| US-20110184015-A1 | NOVEL DERIVATIVES OF PYRROLOINDOLE WHICH ARE INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | IDO1 2273/4885ADORA2A 3659/4885SMN1; SMN2 3622/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | IDO1 2394/4885ADORA2A 1442/4885SMN1; SMN2 4633/4885 |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | HSP90AB2P, HSPA2, HSP90AB1 | IDO1 4758/4885ADORA2A 3671/4885SMN1; SMN2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.